Cargando…
Development and Technical Validation of an Immunoassay for the Detection of APP(669–711) (Aβ(−3–40)) in Biological Samples
The ratio of amyloid precursor protein (APP)(669–711) (Aβ(−3–40))/Aβ(1–42) in blood plasma was reported to represent a novel Alzheimer’s disease biomarker. Here, we describe the characterization of two antibodies against the N-terminus of Aβ(−3–x) and the development and “fit-for-purpose” technical...
Autores principales: | Klafki, Hans W., Rieper, Petra, Matzen, Anja, Zampar, Silvia, Wirths, Oliver, Vogelgsang, Jonathan, Osterloh, Dirk, Rohdenburg, Lara, Oberstein, Timo J., Jahn, Olaf, Beyer, Isaak, Lachmann, Ingolf, Knölker, Hans-Joachim, Wiltfang, Jens |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555726/ https://www.ncbi.nlm.nih.gov/pubmed/32911706 http://dx.doi.org/10.3390/ijms21186564 |
Ejemplares similares
-
Solid‐Phase Synthesis and Characterization of N‐Terminally Elongated Aβ(−3–x)‐Peptides
por: Beyer, Isaak, et al.
Publicado: (2016) -
A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer’s disease
por: Shahpasand-Kroner, Hedieh, et al.
Publicado: (2018) -
Diagnostic performance of automated plasma amyloid-β assays combined with pre-analytical immunoprecipitation
por: Klafki, Hans-W., et al.
Publicado: (2022) -
ADAMTS4 is involved in the production of the Alzheimer disease amyloid biomarker APP669-711
por: Matsuzaki, Masaya, et al.
Publicado: (2023) -
A Combination of Caffeine Supplementation and Enriched Environment in an Alzheimer’s Disease Mouse Model
por: Stazi, Martina, et al.
Publicado: (2023)